Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-06-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-0162PMID 27301700PMCID PMC5156592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

  2016cited by this paper
• Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

  2016cited by this paper
• TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

  2015cited by this paper
• Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

  2015cited by this paper
• Anthracycline-Induced Cardiomyopathy in Adults.

  2015cited by this paper
• Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer

  2015cited by this paper
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

  2015influential reference
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

  2015cited by this paper
• Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

  2015cited by this paper
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

  2015cited by this paper
• Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State

  2015cited by this paper
• Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

  2014cited by this paper
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014cited by this paper
• Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)

  2014cited by this paper
• Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

  2014cited by this paper
• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

  2014influential reference
• Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

  2014cited by this paper
• Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

  2014cited by this paper
• Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

  2014cited by this paper
• Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

  2014cited by this paper
• Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

  2014cited by this paper
• Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

  2012cited by this paper
• Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

  2011cited by this paper
• Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

  2011cited by this paper
• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• TNM Classification of Malignant Tumors, 7th edition

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• San Antonio Breast Cancer Symposium.

  2009cited by this paper
• High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.

  2009cited by this paper
• Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

  2008cited by this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

  2007cited by this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• X chromosomal abnormalities in basal-like human breast cancer.

  2006cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

  2005cited by this paper
• Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer.

  2005cited by this paper
• Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers.

  2004cited by this paper
• Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER

  2000cited by this paper
• Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines

  1999influential reference
• Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

  1999cited by this paper
• TNM Classification of Malignant Tumors

  1998cited by this paper
• TNM classification of malignant tumors, fifth edition (1997)

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper

• The emerging role of nicotinamide N-methyltransferase in the pathogenesis and treatment of breast cancer.

  2026cites this paper
• Sacituzumab Govitecan in the Treatment of Triple-Negative Breast Cancer: Present and Future

  2025cites this paper
• New Perspectives in the Management of Triple-Negative Breast Cancer.

  2025cites this paper
• Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

  2025cites this paper
• Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms

  2025cites this paper
• Advancing breast cancer therapy in the era of molecular diagnostics

  2025cites this paper
• Ki-67 Levels and Their Association With Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Prospective Observational Study

  2025influential citation
• Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

  2025cites this paper
• Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer

  2025cites this paper
• Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models

  2025cites this paper
• Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer

  2025cites this paper
• Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.

  2024cites this paper
• Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses

  2024cites this paper
• Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms

  2024cites this paper
• TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

  2024cites this paper
• FOXO4 suppresses cisplatin resistance of Triple-Negative Breast Cancer by inhibiting autophagy.

  2024cites this paper
• Current treatment paradigms for triple-negative breast cancer.

  2024cites this paper
• Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II–III triple negative breast cancer: a retrospective analysis

  2024cites this paper
• Challenges in the management of operable triple-negative breast cancer in a survivor of the B-cell acute lymphoblastic leukemia: a case report

  2024cites this paper
• Triple-negative accessory breast cancer occurring concurrently with primary invasive breast carcinoma: a case report

  2024cites this paper
• A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

  2024cites this paper
• Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial.

  2023cites this paper
• Efficacy and safety of apatinib combined with dose‐dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis

  2023influential citation
• Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC)

  2023cites this paper
• Prognostic Value Of Basal Markers (Epidermal Growth Factor Receptor "EGFR" And Cytokeratin 5/6) Expression In Triple-Negative Invasive Breast Cancer.

  2023cites this paper
• Functional inhibition of the RNA‐binding protein HuR sensitizes triple‐negative breast cancer to chemotherapy

  2023cites this paper
• Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

  2023cites this paper
• An overview of the research progress of BRCA gene mutations in breast cancer.

  2023cites this paper
• Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance

  2023cites this paper
• Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial

  2023cites this paper
• BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

  2022cites this paper
• Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis

  2022influential citation
• A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

  2022cites this paper
• Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach

  2022cites this paper
• Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells

  2022cites this paper
• Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer.

  2022cites this paper
• 'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.

  2022cites this paper
• Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

  2022cites this paper
• A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer

  2022cites this paper
• An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

  2022cites this paper
• Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials

  2022cites this paper
• Impact of body mass index on pathological complete response and survival of breast cancer patients receiving neoadjuvant chemotherapy

  2022cites this paper
• Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents

  2022cites this paper
• Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer

  2022cites this paper
• Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study

  2022cites this paper
• Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study

  2022cites this paper
• In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer

  2022cites this paper
• Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?

  2022cites this paper
• Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial

  2022cites this paper
• Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer

  2022cites this paper
• Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies

  2022cites this paper
• Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature

  2022influential citation
• Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer.

  2022cites this paper
• Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases

  2022cites this paper
• CAN-21-3714 2281..2297

  2022cites this paper
• Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis

  2022cites this paper
• Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

  2022cites this paper
• Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo

  2022cites this paper
• A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

  2021cites this paper
• Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer

  2021cites this paper
• Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.

  2021cites this paper
• In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach

  2021cites this paper
• Chemotherapy coupled to macrophage inhibition leads to enhanced T and B cell infiltration and durable triple negative breast cancer regression

  2021cites this paper
• Nomogram for chemotherapy decision-making in patients with small triple-negative breast tumor: A population-based study

  2021cites this paper
• Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

  2021cites this paper
• Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple‐negative, early‐stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open‐label phase II trial

  2021cites this paper
• A careful reassessment of anthracycline use in curable breast cancer

  2021cites this paper
• Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis

  2021cites this paper
• Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review

  2021cites this paper
• The Effect of Chemotherapy on Estradiol Levels in Patients with HER 2-Overexpression Breast Cancer in Dr Moewardi General Hospital, Surakarta, Indonesia

  2021cites this paper
• BCTT_A_292161 87..105

  2021cites this paper
• Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors

  2020cites this paper
• Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology

  2020cites this paper
• OP-JNCI200081 1..5

  2020cites this paper
• Primary multiple BRCA associated breast cancer and ovarian cancer (clinical case)

  2020cites this paper
• Homologous recombination-deficient cancers: approaches to improve treatment and patient selection

  2020cites this paper
• Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer.

  2020influential citation
• Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

  2020cites this paper
• Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer.

  2020cites this paper
• Progress in systemic therapy for triple-negative breast cancer

  2020cites this paper
• Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond

  2020cites this paper
• Platinum-based drugs in neoadjuvant treatment of patients with triple-negative breast cancer

  2020cites this paper
• Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges

  2020cites this paper
• A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.

  2020cites this paper
• Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond

  2020cites this paper
• Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy.

  2020cites this paper
• Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

  2020cites this paper
• Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.

  2020cites this paper
• BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.

  2020cites this paper
• A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

  2020cites this paper
• Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

  2020cites this paper
• Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy

  2020cites this paper
• Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.

  2019cites this paper
• Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical 18F-FDG PET Imaging of Triple-Negative Breast Cancer Patient–Derived Tumor Xenografts

  2019cites this paper
• Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis

  2019cites this paper
• Sonographically guided metalic clip placement for tumour localization in early breast cancer patients undergoing neoadjuvant chemotherapy.

  2019cites this paper
• Oncogenética: cánceres de mama hereditarios

  2019cites this paper
• Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

  2019influential citation
• Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

  2019cites this paper
• Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

  2019cites this paper